Efficacy and safety of ketamine in the management of anxiety and anxiety spectrum disorders: a review of the literature.
Date
2020-06
Journal Title
Journal ISSN
Volume Title
Repository Usage Stats
views
downloads
Citation Stats
Abstract
Anxiety disorders are among the most prevalent psychiatric conditions. Despite many proven pharmacological and non-pharmacological treatments available, high rates of partial response and low rates of long-term remission remain. Ketamine has been receiving increasing attention as an interventional treatment modality in psychiatry, especially among refractory conditions, including major depressive disorder. There is limited yet growing evidence to support the use of ketamine in anxiety disorders. In this review of the literature, we present case reports, case series, and controlled trials demonstrating proof-of-concept for its potential role in the treatment of anxiety and anxiety spectrum disorders. Its unique mechanism of action, rapid onset, and high rate of response have driven its use in clinical practice. Ketamine is generally well tolerated by patients and has a limited side effect profile; however, the effects of long-term use are unknown. While there is a growing body of research and increasing clinical experience to suggest ketamine may have clinical applications in the treatment of refractory anxiety disorders, further research to determine long-term safety and tolerability is indicated.
Type
Department
Description
Provenance
Citation
Permalink
Published Version (Please cite this version)
Publication Info
Banov, Michael D, Jonathan R Young, Tyler Dunn and Steven T Szabo (2020). Efficacy and safety of ketamine in the management of anxiety and anxiety spectrum disorders: a review of the literature. CNS spectrums, 25(3). pp. 331–342. 10.1017/s1092852919001238 Retrieved from https://hdl.handle.net/10161/21644.
This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.
Collections
Scholars@Duke
Jonathan Young
Jonathan Robert Young, MD is Assistant Consulting Professor at Duke Department of Psychiatry & Behavioral Sciences, and Staff Psychiatrist at Durham VA Health Care System, Treatment Refractory Disorders Clinic. He is a member of the Division of Behavioral Medicine & Neurosciences where he has served as an attending physician in the Duke electroconvulsive therapy (ECT) clinic. His research interests focus on clinical applications of non-invasive neuromodulation technologies such as repetitive transcranial magnetic stimulation (rTMS) for the treatment of psychiatric and substance use disorders. Currently, Dr. Young is developing a multimodal smoking cessation intervention for Veterans with posttraumatic stress disorder (PTSD) who smoke utilizing functional-connectivity magnetic resonance imaging (fc-MRI) to guide a personalized and accelerated rTMS course in addition to cognitive behavioral therapy (CBT) and nicotine replacement therapy (NRT).
Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.